Femasys Inc. (FEMY)

Femasys Inc. is a biomedical company focused on developing and commercializing innovative solutions for the women's healthcare market. Their portfolio includes products for permanent birth control, artificial insemination, and uterine cancer detection.

59/100 AI Score Target $5.17 (+854.1%) MCap $32.22M Vol 165.77K

Company Overview

CEOKathy Lee-Sepsick
Employees69
HeadquartersSuwanee, GA, US
IPO Year2021

Femasys Inc. pioneers innovative solutions in the women's healthcare market, offering a suite of products from permanent birth control to fertility solutions, addressing unmet needs with non-surgical technologies and capitalizing on a growing global market, despite current profitability challenges.

Investment Thesis

Femasys presents a compelling investment opportunity within the women's healthcare sector, driven by its innovative product portfolio and focus on non-surgical solutions. The company's potential for growth is significant, particularly with its FemBloc and FemaSeed products targeting large and underserved markets. While Femasys currently faces profitability challenges, as reflected in its negative P/E ratio of -0.74 and a profit margin of -960.5%, the company's gross margin of 42.4% indicates the potential for improved financial performance as it scales its commercial operations. Key value drivers include successful clinical trials, regulatory approvals, and market adoption of its products. Upcoming catalysts include potential partnerships and expansion into new geographic markets. Investors should consider the company's high beta of -2.54, indicating high volatility, when making investment decisions.

Key Highlights

  • Market capitalization of $0.01 billion, reflecting its small-cap status and growth potential.
  • Negative P/E ratio of -0.74, indicating current losses but potential for future earnings growth.
  • Profit margin of -960.5%, highlighting the need for improved operational efficiency and revenue generation.
  • Gross margin of 42.4%, demonstrating the potential for profitability as sales increase and costs are managed.
  • Beta of -2.54, suggesting high volatility and a negative correlation with the overall market.

Competitors

Strengths

  • Innovative product portfolio addressing unmet needs in women's healthcare.
  • Focus on non-surgical solutions, offering less invasive options.
  • Proprietary technology and patented products.
  • Established distribution network in key markets.

Weaknesses

  • Limited financial resources and profitability challenges.
  • Dependence on regulatory approvals for product launches.
  • Small market capitalization and high stock volatility.
  • Competition from larger, more established medical device companies.

Catalysts

  • Upcoming: FDA approval and commercial launch of FemBloc.
  • Ongoing: Expansion of FemVue sales in existing markets.
  • Upcoming: Positive clinical trial results for FemEMB.
  • Ongoing: Strategic partnerships to expand market reach.

Risks

  • Potential: Delays in regulatory approvals for key products.
  • Ongoing: Competition from established medical device companies.
  • Potential: Product liability claims.
  • Ongoing: Dependence on key personnel.
  • Potential: Inability to secure additional funding.

Growth Opportunities

  • Growth opportunity 1: Expansion of FemVue Commercialization: Femasys has the opportunity to further expand the commercialization of its FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The global market for fallopian tube assessment is estimated to be worth hundreds of millions of dollars annually. By increasing its sales and marketing efforts, Femasys can capture a larger share of this market and drive revenue growth. Timeline: Ongoing.
  • Growth opportunity 2: Regulatory Approval and Launch of FemBloc: Femasys is developing FemBloc, a permanent birth control solution. Successful completion of clinical trials and subsequent regulatory approval by the FDA would represent a significant growth catalyst. The market for permanent birth control is substantial, with millions of women seeking safe and effective options. Timeline: 2-3 years.
  • Growth opportunity 3: Commercialization of FemaSeed: FemaSeed, Femasys' artificial insemination solution, presents another growth opportunity. By targeting the growing infertility market, Femasys can generate revenue and establish itself as a key player in the reproductive health space. The global artificial insemination market is projected to reach billions of dollars in the coming years. Timeline: 1-2 years.
  • Growth opportunity 4: Development and Launch of FemEMB: Femasys is developing FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. Successful development and launch of this product would address a critical need in women's health and contribute to revenue growth. The market for uterine cancer detection is significant, driven by the increasing incidence of the disease. Timeline: 3-5 years.
  • Growth opportunity 5: Strategic Partnerships and Acquisitions: Femasys can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the women's health space can accelerate growth and create synergies. This includes potential partnerships for distribution, co-development, or licensing agreements. Timeline: Ongoing.

Opportunities

  • Expansion into new geographic markets.
  • Strategic partnerships and acquisitions.
  • Increasing awareness of women's health issues and demand for advanced solutions.
  • Development of new products and applications for existing technologies.

Threats

  • Regulatory hurdles and delays in product approvals.
  • Competition from existing and emerging medical device companies.
  • Changes in healthcare regulations and reimbursement policies.
  • Potential product liability claims.

Competitive Advantages

  • Patented technologies provide a competitive advantage.
  • Focus on non-surgical solutions differentiates them from competitors.
  • Established relationships with key healthcare providers.
  • Specialized expertise in women's healthcare.

About

Femasys Inc., established in 2004 and headquartered in Suwanee, Georgia, is a biomedical company dedicated to transforming women's healthcare through the development and commercialization of innovative solutions. The company's core focus lies in addressing unmet needs within the women's health market, particularly in areas such as permanent birth control, fertility, and uterine health. Femasys' product portfolio includes FemBloc and FemChec, permanent birth control solutions; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling for uterine cancer detection. Additionally, the company commercializes FemVue, a saline-air device used in fallopian tube assessment, across the United States, Europe, Canada, Japan, and other international markets. Femasys distinguishes itself by offering non-surgical product technologies, aiming to provide less invasive and more accessible options for women. The company targets obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists as its primary customer base, reflecting its commitment to serving the broader women's healthcare ecosystem.

What They Do

  • Develop permanent birth control solutions (FemBloc and FemChec).
  • Offer an artificial insemination solution (FemaSeed).
  • Provide a biopsy device for endocervical curettage (FemCerv).
  • Develop a product for endometrial sampling in uterine cancer detection testing (FemEMB).
  • Commercialize FemVue, a saline-air device for fallopian tube assessment.
  • Offer non-surgical product technologies for women's healthcare.

Business Model

  • Develop and patent innovative medical devices for women's health.
  • Obtain regulatory approvals for their products.
  • Manufacture and market their products to healthcare providers.
  • Generate revenue through direct sales and distribution agreements.

Industry Context

Femasys operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by continuous innovation, driven by the need for more effective and less invasive medical solutions. The women's healthcare market, in particular, is experiencing growth due to increasing awareness of women's health issues and a growing demand for advanced medical technologies. Femasys competes with companies like AIMD, APLM, BCTX, COCH, and CRIS, all of which are developing and marketing medical devices and solutions. The company's focus on non-surgical approaches and its unique product portfolio position it to capture a significant share of this expanding market.

Key Customers

  • Obstetrics-gynecological physicians
  • Related healthcare professionals
  • Women's healthcare provider organizations
  • Reproductive endocrinologists
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $729,394 -$4M $-0.15
Q2 2025 $409,268 -$5M $-0.16
Q1 2025 $341,264 -$6M $-0.23
Q4 2024 $581,576 -$5M $-0.22

Source: Company filings

Chart & Info

Price Chart

Femasys Inc. (FEMY) stock price: $0.54 (-0.00, -0.82%)

Why Bull

  • •Femasys has recently seen positive insider activity, indicating confidence from leadership in the company's direction.
  • •Community sentiment has shifted favorably, with discussions highlighting the potential of Femasys' innovative products in women's health.
  • •Bullish sentiment is driven by recent clinical trial updates that suggest promising results, enhancing investor optimism.
  • •Market perception is buoyed by increasing awareness of women's health issues, positioning Femasys as a key player in this growing sector.

Why Bear

  • •Despite some positive developments, there are concerns about the company's ability to scale operations effectively in a competitive market.
  • •Recent bearish sentiment in forums reflects skepticism about the sustainability of Femasys' growth trajectory amid potential regulatory hurdles.
  • •Investors are cautious due to the company's relatively small market presence, raising doubts about long-term viability against larger competitors.
  • •Market perception is tempered by broader economic uncertainties, which could impact funding and investment in healthcare startups like Femasys.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for FEMY including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Femasys Inc. (FEMY) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for FEMY.

Make a Prediction

Set your price target for Femasys Inc. (FEMY), choose a timeframe, and track your prediction accuracy.

Current price: $0.54 · Analyst target: $5.17

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FEMY.

Price Targets

Consensus target: $5.17

Insider Flow (30d)

Lee-Sepsick Kathy
Insider
3 days ago
BOUGHT
729,000 shares
Elefant Dov
Insider
3 days ago
BOUGHT
342,000 shares

MoonshotScore

58.5/100

Score Factors

  • Revenue Growth 8/100

    Revenue grew 52.0% YoY, showing strong top-line momentum well above industry average.

  • Gross Margin 10/100

    Gross margin of 63.1% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 6/100

    Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    News sentiment is mixed, with a balance of positive and negative coverage in recent days.

What does this score mean?

The MoonshotScore rates FEMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Femasys Inc. do?

Femasys Inc. is a biomedical company focused on developing and commercializing innovative solutions for the women's healthcare market. Their product portfolio includes devices for permanent birth control (FemBloc and FemChec), artificial insemination (FemaSeed), endocervical curettage (FemCerv), endometrial sampling for uterine cancer detection (FemEMB), and fallopian tube assessment (FemVue). The company aims to provide less invasive and more accessible options for women's healthcare needs, targeting obstetrics-gynecological physicians, related healthcare professionals, and reproductive endocrinologists.

Is FEMY stock a good buy?

FEMY stock presents a high-risk, high-reward investment opportunity. While the company has innovative products and a focus on a growing market, it currently faces profitability challenges, as indicated by its negative P/E ratio and profit margin. The potential for growth is significant, particularly with the anticipated launch of FemBloc and expansion of FemVue sales. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in FEMY, taking into account its small market capitalization and high stock volatility.

What are the main risks for FEMY?

The main risks for FEMY include potential delays in regulatory approvals for key products, competition from larger and more established medical device companies, the possibility of product liability claims, dependence on key personnel, and the need to secure additional funding. The company's small size and limited financial resources make it particularly vulnerable to these risks. Additionally, changes in healthcare regulations and reimbursement policies could negatively impact FEMY's business.

Is FEMY a good stock to buy?

Whether FEMY is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the FEMY MoonshotScore?

The MoonshotScore for FEMY is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is FEMY data updated?

FEMY stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to FEMY is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for FEMY?

Growth catalysts for Femasys Inc. (FEMY) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Femasys Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are FEMY's main competitors?

Femasys Inc. (FEMY) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether FEMY has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about FEMY?

Wall Street analyst coverage for FEMY includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is FEMY's market cap?

Market capitalization (market cap) for FEMY is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows FEMY's current market cap alongside enterprise value and other valuation metrics.

How has FEMY stock performed recently?

FEMY's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing FEMY's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in FEMY?

Key risk categories for FEMY include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures FEMY's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling FEMY?

Insider trading activity for FEMY tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is FEMY a good stock for beginners?

Femasys Inc. (FEMY) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is FEMY for first-time investors?

Every stock carries risk, including Femasys Inc. (FEMY). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like FEMY.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data may be outdated.
  • Future performance is subject to market conditions and company-specific factors.
Data Sources
profilefundamentalsexistingCopy